TGFB2 and melanoma: Recently, we confirmed the antitumor immune potential of TGF-β2 inhibition by an antisense oligonucleotide (ASO) and suggested the possibility of using it in combination with an immunostimulator (IL-2) in the breast cancer and melanoma models [22,23].